Alps Advisors Inc Coherus Bio Sciences, Inc. Transaction History

Alps Advisors Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$5.86 - $13.23 $465,401 - $1.05 Million	-79,420 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$10.92 - $16.41 $103,073 - $154,893	-9,439 Reduced 10.62%	79,420 $1.03 Million
Q4 2021 Feb 09, 2022	SELL	$15.81 - $18.99 $77,042 - $92,538	-4,873 Reduced 5.2%	88,859 $1.42 Million
Q3 2021 Nov 15, 2021	SELL	$12.68 - $17.79 $76,561 - $107,416	-6,038 Reduced 6.05%	93,732 $1.51 Million
Q2 2021 Aug 11, 2021	SELL	$12.95 - $15.41 $413,428 - $491,964	-31,925 Reduced 24.24%	99,770 $1.38 Million
Q1 2021 May 07, 2021	SELL	$14.42 - $21.39 $165,426 - $245,386	-11,472 Reduced 8.01%	131,695 $1.92 Million
Q4 2020 Feb 03, 2021	BUY	$16.56 - $18.94 $625,222 - $715,079	37,755 Added 35.82%	143,167 $2.49 Million
Q3 2020 Nov 04, 2020	SELL	$17.41 - $19.89 $111,928 - $127,872	-6,429 Reduced 5.75%	105,412 $1.93 Million
Q2 2020 Aug 05, 2020	SELL	$14.43 - $19.16 $468,224 - $621,703	-32,448 Reduced 22.49%	111,841 $2 Million
Q1 2020 May 06, 2020	BUY	$11.67 - $22.53 $34,123 - $65,877	2,924 Added 2.07%	144,289 $2.34 Million
Q4 2019 Feb 07, 2020	BUY	$16.33 - $21.37 $2.31 Million - $3.02 Million	141,365 New	141,365 $2.55 Million

132

76.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $91.7M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.